Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438955 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL2763479 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL3802461 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL186279 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL82462 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL17514076 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL14959742 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL1131702 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL8120379 | 0.89 | DPP4 (0.52) | DPP4KDM4EADRA2AADRA2CLMNA | |
| Alcohol SCHEMBL8325116 | 0.89 | KDM4E (0.57) | DPP4KDM4EADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004608-B1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LTD (IN) | 2011-09-14 | — | — | EP | claimed |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | claimed |
| US-11860084-B2 | Quantitative auxiliary-free chirality sensing with a metal probe | GEORGETOWN UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11860084-B2 | Quantitative auxiliary-free chirality sensing with a metal probe | GEORGETOWN UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220113247-A1 | QUANTITATIVE AUXILIARY-FREE CHIRALITY SENSING WITH A METAL PROBE | GEORGETOWN UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| WO-2020238559-A1 | DE-C2-SYMMETRIC DIPHENYLAMINE-TYPE CHIRAL BISOXAZOLINE LIGAND, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 浙江工业大学 | 2020-12-03 | — | — | WO | disclosed |
| EP-2970237-B1 | HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9758495-B2 | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758495-B2 | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9175006-B2 | Compositions and methods for cyclofructans as separation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2014151863-A1 | HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-1647546-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-6239316-B1 | Optically active secondary alcohol and process for the production thereof | MITSUBISHI GAS CHEMICAL COMPANY INC (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0980860-A1 | Optically active secondary alcohol and process for the production thereof | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2000-02-23 | — | — | EP | disclosed |
| EP-0893422-A1 | Optically active alcohol and process for the production thereof | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1999-01-27 | — | — | EP | disclosed |
| US-5089642-A | Using diphenyl hydroxyl amines coupled to support by amine nitrogen as separation agents | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1992-02-18 | — | — | US | disclosed |
| US-5041573-A | Chromatography separation | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| US-4966985-A | Optically active carboalkylated amino alcohols and their utilization in optical resolution | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0231515-B1 | UTILISATION OF OPTICALLY ACTIVE CARBOALKYLATED AMINO ALCOHOLS IN OPTICAL RESOLUTION | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0231515-A1 | Utilisation of optically active carboalkylated amino alcohols in optical resolution | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CMA1, MED1, MPST | DPP4 1092/4885KDM4E 404/4885ADRA2A 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.